TScan Therapeutics, Inc.
General ticker "TCRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $264.4M (TTM average)
TScan Therapeutics, Inc. follows the US Stock Market performance with the rate: 6.3%.
Estimated limits based on current volatility of 5.7%: low 0.96$, high 1.08$
Factors to consider:
- Total employees count: 195 as of 2024
- Top business risk factors: Economic downturns and volatility, Biotech product development risks, Liquidity and credit risks, Cybersecurity threats, Manufacturing risks
- Current price 30.2% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.56$, 4.36$]
- 2025-12-31 to 2026-12-31 estimated range: [1.17$, 3.22$]
Financial Metrics affecting the TCRX estimates:
- Positive: with PPE of -2.6 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -33.07 <= 0.33
- Positive: Inventory ratio change, % of -48.09 <= -0.75
- Positive: Interest expense per share per price, % of 1.09 <= 3.41
- Negative: negative Industry operating cash flow (median)
Short-term TCRX quotes
Long-term TCRX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $13.54MM | $21.05MM | $2.82MM |
| Operating Expenses | $80.17MM | $114.51MM | $137.64MM |
| Operating Income | $-66.64MM | $-93.46MM | $-134.82MM |
| Non-Operating Income | $0.83MM | $8.48MM | $7.32MM |
| Interest Expense | $1.18MM | $3.76MM | $3.65MM |
| R&D Expense | $59.82MM | $88.15MM | $107.35MM |
| Income(Loss) | $-65.81MM | $-84.98MM | $-127.50MM |
| Profit(Loss)* | $-66.22MM | $-89.22MM | $-127.50MM |
| Stockholders Equity | $99.43MM | $150.87MM | $240.97MM |
| Assets | $199.09MM | $272.15MM | $371.12MM |
| Operating Cash Flow | $-66.50MM | $-61.36MM | $-110.82MM |
| Capital expenditure | $4.22MM | $3.15MM | $3.83MM |
| Investing Cash Flow | $-4.22MM | $-60.76MM | $-52.61MM |
| Financing Cash Flow | $29.36MM | $135.44MM | $208.76MM |
| Earnings Per Share** | $-2.75 | $-1.36 | $-1.14 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.